INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 28 February 2015
|
Net Assets |
£238m |
|
Net Assets per share |
570p |
|
Share price |
495p |
|
Total value of unquoted investments |
£18m |
|
Total number of portfolio companies |
88 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Biogen-Idec |
8.4 |
|
Celgene |
8.0 |
|
Gilead |
6.2 |
|
Amgen |
4.7 |
|
Chimerix |
4.7 |
|
Vertex |
4.7 |
|
Pharmacyclics |
3.6 |
|
Regeneron |
3.6 |
|
Alexion |
3.1 |
|
Cempra |
3.0 |
|
|
----------- |
|
Total |
50.0 |
|
Portfolio Profitability |
% NAV |
|
Profitable |
51 |
|
Turning Profitable 2015 |
6 |
|
Unprofitable |
43 |
|
|
----------- |
|
Total |
100 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
90 |
|
Europe & UK |
10 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
93 |
|
Unquoted |
7 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
23 MARCH 2015